Interaction of membrane-bound islet amyloid polypeptide with soluble and crystalline insulin

被引:73
作者
Knight, Jefferson D. [2 ]
Williamson, Jessica A. [1 ]
Miranker, Andrew D. [1 ]
机构
[1] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA
[2] Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA
关键词
islet amyloid polypeptide; insulin; amyloid inhibition; protein-membrane interactions; peptide-crystal interactions; amylin; protein aggregation;
D O I
10.1110/ps.036350.108
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Islet amyloid polypeptide (IAPP, also known as amylin) is the major protein component of pancreatic amyloid fibers in type II diabetes and is normally cosecreted with insulin from the beta-cells of the pancreas. IAPP forms amyloid fibrils rapidly at concentrations well below those found in vivo, yet progression of type II diabetes occurs over many years. Insulin, a known inhibitor of IAPP fibrillogenesis, exists as a dense crystalline or near-crystalline core in the secretory vesicle, while IAPP localizes to the region between the crystal and the secretory vesicle membrane. In vitro, IAPP fibrillogenesis is both accelerated by lipid membranes and inhibited by monomeric insulin. In this work, we investigate insulin-IAPP-lipid interactions in vitro under conditions chosen to approximate native secretory vesicle physiology and the amyloid disease state. The effect of insulin on IAPP fibrillogenesis is investigated using fluorescence spectrometry. Additionally, interactions of IAPP and lipids with crystalline insulin are studied using fluorescence microscopy. We find that, while soluble states of insulin and IAPP do not interact significantly, large assemblies of either insulin (crystals) or IAPP (fibers) can lead to stable IAPP-insulin interactions. The results raise the possibility of multiple physiological interactions between these two beta-cell hormones.
引用
收藏
页码:1850 / 1856
页数:7
相关论文
共 41 条
[1]   Structure of α-helical membrane-bound human islet amyloid polypeptide and its implications for membrane-mediated misfolding [J].
Apostolidou, Melania ;
Jayasinghe, Sajith A. ;
Langen, Ralf .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (25) :17205-17210
[2]   THE STRUCTURE OF 2ZN PIG INSULIN CRYSTALS AT 1.5-A RESOLUTION [J].
BAKER, EN ;
BLUNDELL, TL ;
CUTFIELD, JF ;
CUTFIELD, SM ;
DODSON, EJ ;
DODSON, GG ;
HODGKIN, DMC ;
HUBBARD, RE ;
ISAACS, NW ;
REYNOLDS, CD ;
SAKABE, K ;
SAKABE, N ;
VIJAYAN, NM .
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES, 1988, 319 (1195) :369-&
[3]   An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures [J].
Bennett, RG ;
Hamel, FG ;
Duckworth, WC .
DIABETES, 2003, 52 (09) :2315-2320
[4]  
Blundell T., 1972, ADV PROTEIN CHEM, V26, P279, DOI 10.1016/S0065-3233(08)60143-6
[5]   Diabetes due to a progressive defect in β-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat) -: A new model for type 2 diabetes [J].
Butler, AE ;
Jang, J ;
Gurlo, T ;
Carty, MD ;
Soeller, WC ;
Butler, PC .
DIABETES, 2004, 53 (06) :1509-1516
[6]   Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders [J].
Caughey, B ;
Lansbury, PT .
ANNUAL REVIEW OF NEUROSCIENCE, 2003, 26 :267-298
[7]   PANCREATIC EXPRESSION AND SECRETION OF HUMAN ISLET AMYLOID POLYPEPTIDE IN A TRANSGENIC MOUSE [J].
DALESSIO, DA ;
VERCHERE, CB ;
KAHN, SE ;
HOAGLAND, V ;
BASKIN, DG ;
PALMITER, RD ;
ENSINCK, JW .
DIABETES, 1994, 43 (12) :1457-1461
[8]  
DOCHERTY K, 2003, ELLENBERG RIFKINS DI, P23
[9]   Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane [J].
Engel, Maarten F. M. ;
Khemtemourian, Lucie ;
Kleijer, Cecile C. ;
Meeldijk, Hans J. D. ;
Jacobs, Jet ;
Verkleij, Arie J. ;
de Kruijff, Ben ;
Killian, J. Antoinette ;
Hoeppener, Jo W. M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (16) :6033-6038
[10]   HUMAN ISLET AMYLOID POLYPEPTIDE TRANSGENIC MICE AS A MODEL OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS (NIDDM) [J].
FOX, N ;
SCHREMENTI, J ;
NISHI, M ;
OHAGI, S ;
CHAN, SJ ;
HEISSERMAN, JA ;
WESTERMARK, GT ;
LECKSTROM, A ;
WESTERMARK, P ;
STEINER, DF .
FEBS LETTERS, 1993, 323 (1-2) :40-44